SIRT2 inhibition reverses anhedonia in the VGLUT1+/− depression model

Publication date: 29 September 2017
Source:Behavioural Brain Research, Volume 335
Author(s): I. Muñoz-Cobo, F.B. Belloch, T. Díaz-Perdigón, E. Puerta, R.M. Tordera
Some histone deacetylase (HDACs) enzymes have been proposed as epigenetic targets involved in the pathophysiology of depression and antidepressant-like action. Among them, we have recently identified SIRT2, a class III NAD⁺-dependent HDAC, as being oppositely regulated by stress and antidepressants. Moreover, SIRT2 inhibition has shown antianhedonic-like action in the chronic mild stress model of depression. Here we have extended the study using an alternative model of depression based in a genetic manipulation of glutamate function. Specifically, mice heterozygous for the vesicular glutamate transporter 1 (VGLUT1+/−) were used.Firstly, mRNA expression of the different members of the HDAC superfamily in the prefrontal cortex (PFC) of VGLUT1+/− mice and WT littermates were studied by RT-PCR. Secondly, the effect of repeated treatment with the selective SIRT2 inhibitor 33i and the antidepressant imipramine on anhedonic behaviour of VGLUT1+/− mice was studied by weekly monitoring of sucrose intake. Further, the interaction of 33i towards specific monoaminergic targets such as serotonin or noradrenaline transporters as well as the monoaminooxidase enzyme was studied.The mRNA occurance of the different members of HDAC superfamily was not altered in the PFC of VGLUT1+/− mice. While repeated imipramine showed an anti-anhedonic action in both VGLUT1+/− and WT, the selective SIRT2 inhibitor 33i fully reversed anhedonia of VGLUT1+/−. Further, 33i showed no interaction with the above mentioned monoaminergic molecular targets.These results confirm that SIRT2 inhibition is able to reverse anhedonia in different animal models and highlight the need to further investigate the role of SIRT2 inhibitors as new antidepressant agents.



http://ift.tt/2fT0pGf